Contact us

Request access to the first AI system trained on 1M+ outcome-linked papers across 5,846 rare diseases – forecasting probability of success for early-stage therapies years before clinical signals emerge.

  1. De-risk pipeline

Make confident early-stage R&D and investments choices with drug discovery landscapes for 5,846 rare diseases featuring probability of success forecasts.

  1. Monitor opportunities

Continuous monitoring of emerging novel therapies with the highest approval potential, delivered as memorandums personalized to specific pipelines.

  1. Repurpose drugs

Selecting and ranking successful opportunities for therapeutic repurposing by targets and mechanisms across more than 1 million drug discovery publications.

Reach out to our team

We’d love to hear from you. Whether you're selecting next R&D idea, planning your next investment or just have questions - drop us a message. Let’s explore how we can work together to solve rare diseases.

By submitting this form I agree to Terms & Conditions

Woman with a short haircut smiling confidently, wearing a blazer and standing in warm natural light with modern architecture behind her.

Julia Mozyleva

chief business officer

Woman with a short haircut smiling confidently, wearing a blazer and standing in warm natural light with modern architecture behind her.

Julia Mozyleva

chief business officer

From insights to

impact.

impact.

Let's accelerate therapies for rare diseases affecting over 350 million people worldwide.

From insights to

impact.

impact.

Let's accelerate therapies for rare diseases affecting over 350 million people worldwide.

From insights to

impact.

impact.

Let's accelerate therapies for rare diseases affecting over 350 million people worldwide.
Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.